Modification of doxorubicin-induced cardiotoxicity: Manipulation of the dosage schedule

Human and Experimental Toxicology

Volumn 21, Issue 11, 2002, Pages 607-614

  Yeung, T K ^a   Chakrabarti, K ^b   Wilding, D ^b   Hopewell, J W ^b  

^a Northeastern Ontario Regional Cancer Centre   (Canada)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cardiotoxicity; Dose schedules; DOX

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; DOXORUBICIN; EPIRUBICIN; RAZOXANE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG EFFECT; HEART FUNCTION; HEART OUTPUT; HEART PROTECTION; MALE; MULTIPLE DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARDIAC OUTPUT, LOW; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; INJECTIONS, INTRAVENOUS; MALE; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA;

EID: 0036869633     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/0960327102ht300oa     Document Type: Article

References (32)

1. Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs 1997; 54: 1-7.
2. Neri B, Dini-Neri G, Bandinelli M, Bartalucci S, Ciapio A. Doxorubicin and epirubicin cardiotoxicity: experimental and clinical aspect. Int J Clin Pharmacol Ther Toxicol 1989; 27: 217-21.
3. Basser RL, Green R. Strategies for the prevention of anthracycline induced cardiotoxicity. Cancer Treat Rev 1993; 19: 57-77.
4. Von Hoff DD, Rozencweig M, Layard MVV, Slavik M, Muggia FM. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med 1977; 62: 200-208.
5. Von Hoff DD, Layard MVV, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-17.
6. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde S, Sallan SE, Sanders SP Late cardiac effects of doxorubicin for lymphoblastic leukaemia in childhood. N Engl J Med 1991; 21: 324, 843-45.
7. Carlson RW. Reducing the cardiotoxicity of the anthracyclines. Williston Park Oncol 1992; 6: 95-108.
8. Casper ES, Gaynor JJ, Hajdu SI, et al. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer 1991; 68: 1221-29.
9. de-Valeriola D. Dose optimization of anthracyclines. Anticancer Res 1994; 14: 2307-13.
10. Hortobagyi GN, Frye D, Buzdar AU, et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 1989; 63: 37-45.
11. Shapira J, Gotfried M, Lishner M, Ravid M. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. Cancer 1990; 65: 870-73.
12. Umsawaske T, Valdivieso M, Booser DJ, et al. Weekly doxorubicin versus doxorubicin every three weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer. Cancer 1989; 64: 1995-2000.
13. Erttmann R, Erb N, Steinhoff A, et al. Pharmacokinetics of doxorubicin in man; dose and schedule dependence. J Cancer Res Clin Oncol 1988; 114: 509-13.
14. Cusack BJ, Young SP, Driskell J, Olson RD. Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cancer Chemother Pharmacol 1993; 32: 53-58.
15. Storm G, Van Hoesel QGCM, De Groot G, Kop W, Steerenberg PA, Hillen FC. A comparative study of the antitumor effect, cardiotoxicity and nephrotoxicity of doxorubicin given as a bolus, continuous infusion or entrapped in liposomes in the Lou/M Wsl rat. Cancer Chemother Pharmacol 1989; 24: 341-48.
16. Weiss AJ, Manthel RW. A hypothesis concerning the effect of changes in scheduling upon cardiotoxicity of adriamyciiA. Oncology 1983; 40: 223-26.
17. Torti FM, Bristow MR, Howes AE, et al. Reduced cardiotoxicity of doxorubicin delivered on a week schedule. Assessment by endomyocardial biopsy. Ann Intern Med 1983; 99: 745-49.
18. Brenner DE. Approaches to the problem of individual doxorubicin dosing schedules. Pathol Biol (Paris) 1987; 35: 31-39.
19. Yeung TK, Simmonds RH, Hopewell JW. Time- and dose-related modifications in cardiac function in rats after single intravenous doses of epirubicin. Radiother Oncol 1988; 11: 263-69.
20. Yeung TK, Simmonds RH, Hopewell JW. A functional assessment of the relative cardiotoxicity of Adriamycin and epirubicin in the rat. Radiother Oncol 1989; 15: 275-84.
21. Chakrabarti KB, Hopewell JW, Wilding D, Plowman PN. Modification of doxorubicin-induced cardiotoxicity: effect of essential fatty acids and ICRF-187 (dexrazoxane). Eur J Cancer 2001; 37: 1435-42.
22. Hopewell JW, Duncan R, Wilding D, Chakrabarti K. Preclinical evaluation of the cardiotoxicity of PK2: a novel HPMA copolymer-doxorubicin-galactosamine conjugate antitumour agent. Hum Exp Toxicol 2001; 20: 461-70.
23. Yeung TK, Simmonds RH, Hopewell JW. The relative toxicity of intravenous and intraperitoneal doses of epirubicin. Cancer Chemother Pharmacol 1989; 24: 211-18.
24. Yeung TK, Hopewell JW, Simmonds RH, et al. Reduced cardiotoxicity of doxorubicin administered in the form of N-(2-hydroxypropyl)methacrylamide conjugates: an experimental study in the rat. Cancer Chemother Pharmacol 1991; 29: 105-11.
25. Yeung TK, Jaenke RS, Wilding D, Creighton AM, Hopewell JW. The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat. Cancer Chemother Pharmacol 1992; 30: 58-64.
26. Anders RJ, Shanes JG, Zeller FP. Lower incidence of doxorubicin-induced cardiomyopathy by once-a-week low dose administration. Am Heart J 1986; 111: 755-59.
27. Weiss AJ, Metter GE, Fletcher WS. Studies on Adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiotoxicity. Cancer Treat Rep 1976; 60: 813-22.
28. Lum BL, Svec JM, Torti FM. Doxorubicin: alteration of dose scheduling as a means of reducing cardiotoxicity. Drug Intell Clin Pharmacol 1985; 19: 259-64.
29. Valdivieso M, Burgess MA, Ewer MS, et al. Increased therapeutic index of weekly doxorubicin in the therapy of non small cell lung cancer: a prospective randomised study. J Clin Oncol 1984; 2: 207-14.
30. Lippens RJ, van Lier HJ, Zwagemakers JF. Tolerance of 24 hour infusions or low and high dose bolus injections of adriamycin in children. Pediatr Hematol Oncol 1987; 4: 189-97.
31. Chleblowski RT, Pugh RP, Bull F, et al. Concomitant razoxane and doxorubicin treatment on a weekly schedule. Cancer Treat Rep 1984; 68: 1035-37.
32. Withers HR, Peters LJ. Biological basis of radiotherapy. In Fletcher GH ed. Textbook of radiotherapy. New York: Raven Press, 1980: 439-48.